Zoetis Inc. (NYSE:ZTS) Shares Sold by Aigen Investment Management LP

Aigen Investment Management LP reduced its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 22.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 7,720 shares of the company’s stock after selling 2,186 shares during the quarter. Aigen Investment Management LP’s holdings in Zoetis were worth $1,258,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC increased its position in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 140 shares in the last quarter. Darwin Wealth Management LLC acquired a new position in shares of Zoetis in the third quarter valued at about $31,000. First Personal Financial Services acquired a new position in shares of Zoetis in the third quarter valued at about $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis in the third quarter valued at about $33,000. Finally, Dunhill Financial LLC increased its holdings in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

NYSE:ZTS opened at $166.96 on Thursday. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The stock has a market cap of $74.76 billion, a PE ratio of 30.52, a P/E/G ratio of 2.78 and a beta of 0.94. The stock has a 50 day moving average price of $166.57 and a 200 day moving average price of $176.99.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.20%. Zoetis’s dividend payout ratio is presently 36.56%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Barclays increased their price objective on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. StockNews.com lowered Zoetis from a “buy” rating to a “hold” rating in a report on Tuesday, February 25th. Stifel Nicolaus lowered their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Leerink Partners initiated coverage on Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Zoetis has a consensus rating of “Buy” and an average price target of $215.90.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.16% of the company’s stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.